ArticleFrontiers in microbiology2021
An Intranasal Vaccine Based on Outer Membrane Vesicles Against SARS-CoV-2.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- The Role of Gut Microbiota-Derived Extracellular Vesicles in Post-Anesthesia Neuroinflammation and Cognitive Impairment.Journal of Korean Neurosurgical Society · 2026Review
- Outer membrane vesicles inMicrobial cell (Graz, Austria) · 2026Article
- Tiny packages, big potential: bacterial membrane vesicles in vaccinology.Microbial cell factories · 2025Review
- Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.Journal of extracellular vesicles · 2025Review
- Mucosal immunity and vaccination strategies: current insights and future perspectives.Molecular biomedicine · 2025Review
- The Lpp-OmpA-BtaE fusion protein causes a protective immune response against Brucella melitensis in mice.Scientific reports · 2025Article
- RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.Journal of nanobiotechnology · 2025Article
- Opportunities and challenges of bacterial extracellular vesicles in regenerative medicine.Journal of nanobiotechnology · 2025Review
- Orally administered extracellular vesicles fromFrontiers in immunology · 2025Article
- Hybrid response to SARS-CoV-2 andHuman vaccines & immunotherapeutics · 2024Article
- Genetically surface-modifiedBiotechnology reports (Amsterdam, Netherlands) · 2024Article
- Review
- Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2.Current microbiology · 2024Review
- Advances in Nucleic Acid Universal Influenza Vaccines.Vaccines · 2024Review
- Article
- The Two Faces of Bacterial Membrane Vesicles: Pathophysiological Roles and Therapeutic Opportunities.Antibiotics (Basel, Switzerland) · 2023Review
- Localized delivery of nanomedicine and antibodies for combating COVID-19.Acta pharmaceutica Sinica. B · 2023Review
- Bacterial Membrane Vesicles as Smart Drug Delivery and Carrier Systems: A New Nanosystems Tool for Current Anticancer and Antimicrobial Therapy.Pharmaceutics · 2023Review
- Review
- Opportunities for engineering outer membrane vesicles using synthetic biology approaches.Extracellular vesicles and circulating nucleic acids · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The prevailing pandemic of SARS-CoV-2 highlights the desperate need of alternative vaccine-platforms, which are safe, effective, and can be modified to carry antigens of emerging pathogens. The current SARS-CoV-2 vaccines based on mRNA and adenoviral vector technology meet some of these criteria but still face limitations regarding administration route, mass production, stability, and storage. Herein, we introduce a novel SARS-CoV-2 vaccine candidate based on bacterial outer membrane vesicles (OMVs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.